Smartleaf Asset Management’s Amicus Therapeutics FOLD Stock Holding History

Smartleaf Asset Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,025	Closed	-$58.1K	–	3482
2026 Q1	$58.1K	Buy	4,025 +257	+7%	+$3.68K	﹤0.01%	1379
2025 Q4	$53.7K	Buy	3,768 +2,766	+276%	+$27.2K	﹤0.01%	1517
2025 Q3	$7.96K	Buy	1,002 +835	+500%	+$5.94K	﹤0.01%	2205
2025 Q2	$990	Sell	167 -292	-64%	-$1.88K	﹤0.01%	2482
2025 Q1	$3.87K	Sell	459 -198	-30%	-$1.83K	﹤0.01%	2270
2024 Q4	$6.18K	Sell	657 -287	-30%	-$2.98K	﹤0.01%	2175
2024 Q3	$10.1K	Buy	944 +44	+5%	+$479	﹤0.01%	1756
2024 Q2	$8.92K	Buy	+900	New	+$9.24K	﹤0.01%	1471

Other funds holding FOLD

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Smartleaf Asset Management's FOLD Position: Q2 2026 in Review

Smartleaf Asset Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 4,025 shares — an estimated $58.1K sold.

Smartleaf Asset Management first reported a position in FOLD in Q2 2024 and held it in 8 quarters. The position peaked at $58.1K in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

Smartleaf Asset Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
Smartleaf Asset Management sold 4,025 Amicus Therapeutics shares in Q2 2026, an estimated $58.1K.
Smartleaf Asset Management first reported a position in Amicus Therapeutics in Q2 2024 and held it in 8 quarters.
Smartleaf Asset Management's Amicus Therapeutics position peaked at $58.1K in Q1 2026.
2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.